Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
- Cardiotoxicity
- DPP3
- HSCT
- Allogeneic Hematopoietic Stem Cell Transplantation
- ACS - Acute Coronary Syndrome
- Cardiac Dysfunction
- Arrythmia, Cardiac
- Pulmonary Hypertension
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Enrolment target
- 400
- Started
- 25 December 2025
- Main results due
- 25 December 2027
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Aged 15 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Age ≥ 15 years * Informed about the study and without objection to participation (or with consent from legal guardians) * Undergoing allogeneic HSCT Exclusion Criteria: * Patient not followed up at the participating center * Pregnant or breastfeeding women * Patient not affiliated with social security * Patient under guardianship, curatorship, or legal protection
What this study is about
In the sponsor’s own words, from the registry.
Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in HSCT patients remains poorly understood.
It is therefore crucial to investigate underlying mechanisms and identify predictive factors of cardiotoxicity in order to provide appropriate cardiological follow-up and management. Current European Society of Cardiology guidelines recommend routine monitoring of HSCT patients with echocardiography and cardiac biomarkers (NT-proBNP, troponin), although these recommendations are based on small-scale studies. The cardiodepressor factor DPP3 has shown promising results in cardio-oncology, with a causal role in anthracycline-induced cardiac dysfunction. Its role in HSCT-related cardiotoxicity requires further evaluation.
This multicenter study of HSCT recipients will be a valuable resource, enabling a better understanding of the pathophysiology of cardiotoxicity and prognosis. It will highlight imaging (echocardiography, calcium score, supra-aortic Doppler), electrocardiographic, and biological markers (including DPP3) associated with prognosis.
Study sites(1)
Saint Louis Hospital
Paris, France
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07157670. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me